Biotech Alliances International, a San Francisco-based life sciences investment bank, announced today that it is representing Sirbal Ltd. a pharmaceutical company specializing in developing non-toxic herbal treatments based on traditional Chinese medicine. Sirbal is offering for sale its lead asset, SIRB-001, a botanical extract to topically treat dermatological indications.
It is estimated that more than three percent of the worldwide population suffers from noticeable, irritable skin diseases, including psoriasis, atopic dermatitis, seborrhea and acne. Many of the available treatments are prescription-based, expensive and carry significant side effects. SIRB-001-based products provide a non-toxic, OTC alternative to patients suffering from inflammatory dermal conditions that can be used in place of or as a complement to conventional therapies.
“We have now successfully completed five pilot clinical trials based on SIRB-001 with clear indication of strong efficacy and safety,” Nadav Shraibom, Founder & CEO of Sirbal, explained. “In addition, we received a provisional authorization to offer our products for cosmetic sale in Europe. This makes it an opportune time for us to seek an organization with the expertise necessary to bring this product to the market.”
The overall addressable market size for SIRB-001-based products in 2017 is estimated at over $6 billion USD in Europe and $23 billion USD worldwide, and will grow at five percent annually through 2022.
“I am pleased to be representing Sirbal in this transaction,” said Franck Brinkhaus, PhD, CEO of Biotech Alliances International. “It is rewarding to play a role in bringing an important asset like SIRB-001 as a safe and effective dermatological remedy to the market.”
About Biotech Alliances International
Biotech Alliances International, Inc. is a San Francisco-based investment bank serving life sciences companies, private equity and venture capital funds. It provides independent financial and strategic advice including corporate finance, mergers & acquisitions, partnering & licensing, deal sourcing and strategic consulting. For more information: http://www.biotech-alliances.com/
Sirbal Ltd. combines in-depth knowledge of traditional herbal medicine with state-of-the-art scientific tools to develop drugs based on traditional Chinese medicine for treating Inflammatory diseases. Its first compound SIRB-001, targeting numerous dermatological indications, has shown clear efficacy and low toxicity in clinical trials. For more information: http://www.sirbal.com/background
View source version on businesswire.com: http://www.businesswire.com/news/home/20161129006276/en/Business Wire
Last updated on: 30/11/2016
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.